Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
103 trials
Recruiting nowPhase 2
Tislelizumab in People With Colorectal Cancer
Recruiting nowPhase 3
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Recruiting nowPhase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer
Recruiting nowPhase 2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Recruiting nowPhase 2
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Recruiting nowPhase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2
Recruiting nowPhase 2
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Recruiting nowPhase 2
Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors
Recruiting nowPhase 2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Recruiting nowPhase 2
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Recruiting nowPhase 2
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer
Recruiting nowPhase 3
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
Recruiting nowPhase 2
NeoCSR-Omics Trial: CAPOX + Serplulimab Before vs. After Short-course RT in LARC
Recruiting nowPhase 2
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors
Recruiting nowPhase 2
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration